Report date: Apr 30, 2024 Conflict count: 350192 Publisher: SAGE Publications Title count: 528 Conflict count: 29357 ========================================================== Created: 2017-01-12 06:09:06.0 ConfID: 5188286 CauseID: 1400444683 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Dranitsaris, 6 ,2,37,2000,The cost of blood transfusions in cancer patients: a reanalysis of a Canadian economic evaluation DOI: 10.1191/107815500678816205(Journal) (5188286-N ) DOI: 10.1177/107815520000600201(Journal) ========================================================== Created: 2017-01-12 06:09:06.0 ConfID: 5188287 CauseID: 1400444683 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Kolesar, 6 ,2,43,2000,Docetaxel in hepatic impairment DOI: 10.1191/107815500678816214(Journal) (5188287-N ) DOI: 10.1177/107815520000600202(Journal) ========================================================== Created: 2017-01-12 06:09:06.0 ConfID: 5188288 CauseID: 1400444683 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Dooley, 6 ,2,50,2000,Reproducibility of treatment methodologies detailed in contemporary clinical trial reports DOI: 10.1191/107815500678816188(Journal) (5188288-N ) DOI: 10.1177/107815520000600203(Journal) ========================================================== Created: 2017-01-12 06:09:06.0 ConfID: 5188289 CauseID: 1400444683 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Poole, 6 ,2,55,2000,Establishing a baseline incidence of adverse drug reactions in hospitalised oncology patients DOI: 10.1191/107815500678816160(Journal) (5188289-N ) DOI: 10.1177/107815520000600204(Journal) ========================================================== Created: 2017-01-12 06:09:06.0 ConfID: 5188290 CauseID: 1400444683 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Roscoe, 6 ,2,60,2000,A multidisciplinary approach to ensure safety in the prescribing and administration of chemotherapy DOI: 10.1191/107815500678816197(Journal) (5188290-N ) DOI: 10.1177/107815520000600205(Journal) ========================================================== Created: 2017-01-12 06:09:06.0 ConfID: 5188291 CauseID: 1400444683 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Tran, 6 ,2,64,2000,The impact of introducing pre-printed chemotherapy medication charts to a day chemotherapy unit DOI: 10.1191/107815500678816179(Journal) (5188291-N ) DOI: 10.1177/107815520000600206(Journal) ========================================================== Created: 2017-01-12 06:12:04.0 ConfID: 5188419 CauseID: 1400445875 OtherID: 183022205 JT: Journal of Oncology Pharmacy Practice MD: null, 10 ,2,61,2004,Abstracts DOI: 10.1191/1078155204jp121oa(Journal) (5188419-N ) DOI: 10.1177/107815520401000201(Journal) ========================================================== Created: 2017-01-12 06:14:10.0 ConfID: 5188471 CauseID: 1400446752 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: van Gijn, 5 ,4,166,1999,Protein kinase C as a target for new anti-cancer agents DOI: 10.1191/107815599678840525(Journal) (5188471-N ) DOI: 10.1177/107815529900500402(Journal) ========================================================== Created: 2017-01-12 06:14:10.0 ConfID: 5188473 CauseID: 1400446752 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Kapelushnik, 5 ,4,179,1999,Thalidomide does not interfere with graft-versus-leukemia reactivity in mice DOI: 10.1191/107815599678840499(Journal) (5188473-N ) DOI: 10.1177/107815529900500403(Journal) ========================================================== Created: 2017-01-12 06:14:10.0 ConfID: 5188474 CauseID: 1400446752 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: McLennan, 5 ,4,184,1999,Beneficial clinical outcomes resulting from pharmacist interventions DOI: 10.1191/107815599678840471(Journal) (5188474-N ) DOI: 10.1177/107815529900500404(Journal) ========================================================== Created: 2017-01-12 06:14:10.0 ConfID: 5188475 CauseID: 1400446752 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Spina, 5 ,4,190,1999,A retrospective review of gemcitabine use in advanced epithelial ovarian cancer DOI: 10.1191/107815599678840507(Journal) (5188475-N ) DOI: 10.1177/107815529900500405(Journal) ========================================================== Created: 2017-01-12 06:14:10.0 ConfID: 5188476 CauseID: 1400446752 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Hole, 5 ,4,194,1999,Audit of efficacy of 3 mg versus 1 mg of intravenous granisetron as antiemetic prophylaxis against acute emesis caused by cisplatin or melphalan DOI: 10.1191/107815599678840516(Journal) (5188476-N ) DOI: 10.1177/107815529900500406(Journal) ========================================================== Created: 2017-01-12 06:15:56.0 ConfID: 5188491 CauseID: 1400447230 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: null, 6 ,1,3,2000,The Seventh International Symposium on Oncology Pharmacy Practice DOI: 10.1191/107815500678827375(Journal) (5188491-N ) DOI: 10.1177/107815520000600101(Journal) ========================================================== Created: 2017-01-12 06:19:33.0 ConfID: 5188622 CauseID: 1400448659 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Dopp, 5 ,3,109,1999,Risk of breast cancer associated with hormone replacement therapy DOI: 10.1191/107815599678840417(Journal) (5188622-N ) DOI: 10.1177/107815529900500301(Journal) ========================================================== Created: 2017-01-12 06:19:33.0 ConfID: 5188623 CauseID: 1400448659 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Adams, 5 ,3,117,1999,Oprelvekin (Neumega®) DOI: 10.1191/107815599678840390(Journal) (5188623-N ) DOI: 10.1177/107815529900500302(Journal) ========================================================== Created: 2017-01-12 06:19:33.0 ConfID: 5188624 CauseID: 1400448659 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Junker, 5 ,3,125,1999,Antiemetic guidelines: A cooperation between a non-university hospital (Klinikum Remscheid) and a university center (Medical University of Lübeck) in Germany DOI: 10.1191/107815599678840408(Journal) (5188624-N ) DOI: 10.1177/107815529900500303(Journal) ========================================================== Created: 2017-01-12 06:19:33.0 ConfID: 5188625 CauseID: 1400448659 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Paull, 5 ,3,128,1999,Antiemetic guidelines: Royal North Shore Hospital DOI: 10.1191/107815599678840381(Journal) (5188625-N ) DOI: 10.1177/107815529900500304(Journal) ========================================================== Created: 2017-01-12 06:19:33.0 ConfID: 5188626 CauseID: 1400448659 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Bakhshandeh, 5 ,3,131,1999,Year 2000 guidelines for clinical practice of whole body hyperthermia combined with cytotoxic drugs from the University of Lübeck and the University of Wisconsin DOI: 10.1191/107815599678840426(Journal) (5188626-N ) DOI: 10.1177/107815529900500305(Journal) ========================================================== Created: 2017-01-12 06:19:33.0 ConfID: 5188627 CauseID: 1400448659 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Wiedemann, 5 ,3,135,1999,Year 2000 guidelines for the use of antimicrobial agents in adult and pediatric neutropenic patients with unexplained fever from the Universities of Lübeck and Kiel DOI: 10.1191/107815599678840435(Journal) (5188627-N ) DOI: 10.1177/107815529900500306(Journal) ========================================================== Created: 2017-01-12 06:19:33.0 ConfID: 5188628 CauseID: 1400448659 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: null, 5 ,3,139,1999,Reports from the Second Pan-European Oncology Hospital Pharmacy Symposium DOI: 10.1191/107815599678840444(Journal) (5188628-N ) DOI: 10.1177/107815529900500307(Journal) ========================================================== Created: 2017-01-12 06:19:33.0 ConfID: 5188629 CauseID: 1400448659 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Goffredo, 5 ,3,140,1999,The role of the oncology pharmacist in 1999 DOI: 10.1191/107815599678840453(Journal) (5188629-N ) DOI: 10.1177/107815529900500308(Journal) ========================================================== Created: 2017-01-12 06:19:33.0 ConfID: 5188630 CauseID: 1400448659 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Sewell, 5 ,3,143,1999,Oncology pharmacy in the new millennium DOI: 10.1191/107815599678840462(Journal) (5188630-N ) DOI: 10.1177/107815529900500309(Journal) ========================================================== Created: 2017-01-12 06:28:11.0 ConfID: 5189028 CauseID: 1400451641 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Smith, 5 ,1,7,1999,Cancer gene therapy update DOI: 10.1191/107815599678847113(Journal) (5189028-N ) DOI: 10.1177/107815529900500101(Journal) ========================================================== Created: 2017-01-12 06:28:11.0 ConfID: 5189029 CauseID: 1400451641 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Fjornes, 5 ,1,22,1999,Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia DOI: 10.1191/107815599678847122(Journal) (5189029-N ) DOI: 10.1177/107815529900500102(Journal) ========================================================== Created: 2017-01-12 06:28:11.0 ConfID: 5189030 CauseID: 1400451641 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Medina, 5 ,1,32,1999,Treatment of hormone-refractory prostate cancer DOI: 10.1191/107815599678847131(Journal) (5189030-N ) DOI: 10.1177/107815529900500103(Journal) ========================================================== Created: 2017-01-12 06:28:11.0 ConfID: 5189031 CauseID: 1400451641 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Wong, 5 ,1,49,1999,Clinical pharmacy services in oncology clinics DOI: 10.1191/107815599678847104(Journal) (5189031-N ) DOI: 10.1177/107815529900500104(Journal) ========================================================== Created: 2017-01-12 06:28:29.0 ConfID: 5189049 CauseID: 1400451797 OtherID: 684713074 JT: Journal of Oncology Pharmacy Practice MD: null, 14 ,4,233,2008,Erratum DOI: 10.1177/1078155208098835(Journal) (5189049-N ) DOI: 10.1177/1078155208098836(Journal) ========================================================== Created: 2017-01-12 06:34:27.0 ConfID: 5189215 CauseID: 1400453150 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Gilbar, 6 ,3,81,2000,The role of octreotide in symptom management in oncology and palliative care DOI: 10.1191/107815500701563308(Journal) (5189215-N ) DOI: 10.1177/107815520000600302(Journal) ========================================================== Created: 2017-01-12 06:34:27.0 ConfID: 5189216 CauseID: 1400453150 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: van Gijn, 6 ,3,92,2000,Dual topoisomerase I/II inhibitors DOI: 10.1191/107815500701563317(Journal) (5189216-N ) DOI: 10.1177/107815520000600303(Journal) ========================================================== Created: 2017-01-12 06:34:27.0 ConfID: 5189217 CauseID: 1400453150 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Connor, 6 ,3,109,2000,The effect of isopropyl alcohol on the permeation of gloves exposed to antineoplastic agents DOI: 10.1191/107815500701563326(Journal) (5189217-N ) DOI: 10.1177/107815520000600304(Journal) ========================================================== Created: 2017-01-12 06:34:27.0 ConfID: 5189218 CauseID: 1400453150 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Thiesen, 6 ,3,115,2000,Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags DOI: 10.1191/107815500701563335(Journal) (5189218-N ) DOI: 10.1177/107815520000600305(Journal) ========================================================== Created: 2017-01-12 06:34:27.0 ConfID: 5189219 CauseID: 1400453150 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Harrison, 6 ,3,122,2000,Docetaxel-induced extravasation injury: a report of three cases DOI: 10.1191/107815500701563344(Journal) (5189219-N ) DOI: 10.1177/107815520000600306(Journal) ========================================================== Created: 2017-01-12 06:35:30.0 ConfID: 5189267 CauseID: 1400453368 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Harrison, 5 ,2,61,1999,Penetration and splash protection of six disposable gown materials against fifteen antineoplastic drugs DOI: 10.1191/107815599678847159(Journal) (5189267-N ) DOI: 10.1177/107815529900500201(Journal) ========================================================== Created: 2017-01-12 06:35:30.0 ConfID: 5189268 CauseID: 1400453368 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Krug, 5 ,2,67,1999,The K-port concept: Proposal for optimising a fully implantable port system DOI: 10.1191/107815599678847186(Journal) (5189268-N ) DOI: 10.1177/107815529900500202(Journal) ========================================================== Created: 2017-01-12 06:35:30.0 ConfID: 5189269 CauseID: 1400453368 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Krämer, 5 ,2,75,1999,Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices DOI: 10.1191/107815599678847168(Journal) (5189269-N ) DOI: 10.1177/107815529900500203(Journal) ========================================================== Created: 2017-01-12 06:35:30.0 ConfID: 5189270 CauseID: 1400453368 OtherID: 10901856 JT: Journal of Oncology Pharmacy Practice MD: Cabelguenne, 5 ,2,87,1999,Impact of centralization of cytotoxic drug preparations DOI: 10.1191/107815599678847177(Journal) (5189270-N ) DOI: 10.1177/107815529900500205(Journal) ========================================================== Created: 2017-06-29 17:46:22.0 ConfID: 5258009 CauseID: 1408154158 OtherID: 103673404 JT: Journal of Oncology Pharmacy Practice MD: null, 10 ,3,187,2004,Erratum DOI: 10.1191/1078155204jp133xx(Journal) (5258009-N ) DOI: 10.1177/107815520401000309(Journal)